 ABT-510 has been evaluated in three Phase I studies: one single-dose study in healthy volunteers and two studies in cancer patients. Doses ranging from 10 mg to 260 mg have been evaluated as IV infusions 30-minute, subcutaneous bolus injections, or 24-hour subcutaneous infusions. Overall, ABT-510 has been well tolerated. A preliminary review of the 103 case report forms collected to date identified a total of 1306 adverse events. Ninety-one percent 11951306 of these events were considered to be mild or moderate in nature. Eighty-one percent 10521306 of these events were reported as not related to or probably not related to ABT-510. The most common adverse events, occurring in 10 of the patients, include injection site reaction, asthenia, abdominal pain, nausea, anorexia, pain, headache, vomiting, diarrhea, dyspnea, constipation, cough increased, back pain, peripheral edema, dizziness, insomnia, anemia, fever, sweating, chest pain, and rash. 